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For though we may think we are specially blest 
We are certain to pay for the favors we get! 
John Godfrey Saxe 
Inhibition of the angiotensin-converting enzyme has become 
an established approach in the management of patients with 
severe chronic heart failure (1,2). Both captopril and ena-
lapril produce short- and long-term hemodynamic and clin-
ical improvement in these patients (3), and both drugs have 
been shown to be more effective than placebo in randomized 
double-blind clinical trials (4-9). The most recently pub-
lished trial documenting the efficacy of enalapril in ambu-
latory patients with heart failure by Creager et al. (9) appears 
in this issue of the Journal. Other studies (I) suggest that 
the benefits of long-term treatment with captopril are greater 
than can be achieved with other vasodilator drugs, partic-
ularly hydralazine and prazosin. Furthermore, converting 
enzyme inhibition may reduce the frequency of ventricular 
tachyarrhythmias in patients with severe left ventricular dys-
function, perhaps by reducing circulating levels of cate-
cholamines or preserving total body stores of potassium (6). 
By these favorable hemodynamic and antiarrhythmic ac-
tions, long-term therapy with captopril and enalapril may 
prolong survival in selected patients (10,11). This accu-
mulated evidence creates a compelling case for a direct 
deleterious effect of the renin-angiotensin system in severe 
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chronic heart failure, which can be antagonized by treatment 
with converting enzyme inhibitors. 
Is activation of the renin-angiotensin system a mal-
adaptive response? The impressive efficacy of converting 
enzyme inhibitors suggests that activation of the renin-an-
giotensin system in patients with heart failure is a mal-
adaptive response, and we are tempted to conclude that the 
forces of evolution have gone astray. The renin-angiotensin 
system evolved eons ago as a primary attempt to preserve 
circulatory homeostasis at a time when the principal cause 
of low cardiac output was intravascular volume depletion 
(blood loss). Angiotensin U supported systemic blood pres-
sure by I) causing direct systemic vasoco:1striction, 2) fa-
cilitating the central and peripheral effects of the sympa-
thetic nervous system, 3) promoting renal sodium retention 
by stimulating the synthesis of aldosterone, and 4) increas-
ing total body water by stimulating thirst and enhancing the 
synthesis of vasopressin. In addition, angiotensin II evolved 
as an important mechanism to preserve glomerular filtration 
rate in low flow states (12). 
Given its successful role in maintaining circulatory ho-
meostasis in hypovolemic states, it was not surprising that 
the renin-angiotensin system became activated as cardiac 
output decreased in patients with congestive heart failure. 
However, in such cases it appeared as if evolution were 
foolish: the additional systemic vasoconstriction and volume 
expansion mediated by angiotensin II not only were inef-
fective in reversing the low output state of congestive heart 
failure, but further exacerbated loading conditions in the 
left ventricle, leading to clinical deterioration. These det-
rimental effects could be reversed by captopril and enalapril 
(6,7). Convinced that activation of the renin-angiotensin 
system represented an outmoded response with little con-
temporary utility (13), medical scientists began to synthesize 
more potent, more effective and longer-acting converting 
enzyme inhibitors; more than 35 different compounds are 
currently being evaluated by the pharmaceutical industry. 
Yet, before we commit ourselves to this major develop-
mental effort, it is reasonable to ask: Has ev6lution been as 
foolish as we think? Given the critical function of the renin-
angiotensin system in preserving circulatory homeostasis 
over the past several million years, is there no beneficial 
role for angiotensin II in patients with severe heart failure? 
Is the renin-angiotensin system really unnecessary (13)'1 
Recent studies indicate that the renin-angiotensin system 
is activated in most patients (85%) with severe chronic heart 
failure (2), but the magnitude of this activation varies widely. 
Under steady state conditions, serum sodium concentration 
is an accurate marker of the degree of angiotensin II de-
pendence before therapy (14), the greatest activation oc-
curring in patients with the lowest serum sodium concen-
tration. Why is the renin-angiotensin system so highly 
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activated in hyponatremic patients? These patients generally 
have a lower systemic blood pressure and worse renal func-
tion than do patients with a normal serum sodium concen-
tration (15); the enhanced formation of angiotensin II is 
presumably designed (as it was eons ago) to preserve sys-
temic blood pressure and renal function, especially as di-
etary sodium is restricted and as increasing doses of diuretic 
drugs are prescribed in an effort to treat the symptoms of 
congestive heart failure. By focusing on the detrimental 
effects of the renin-angiotensin system on cardiac perform-
ance, we have forgotten its primary directive. Evolution has 
not forgotten, however, and converting enzyme inhibition 
has not been without its hazards. 
Adverse consequences of interfering with the renin-
angiotensin system. Angiotensin II plays an important role 
in preserving cerebral perfusion in patients with severe chronic 
heart failure. Although systemic blood pressure decreases 
in nearly all patients treated with captopril or enalapril, this 
hypotensive response is usually not accompanied by symp-
toms of cerebral hypoperfusion, for example, dizziness or 
blurred vision. Nevertheless, nearly 15% of patients with 
heart failure have hypotensive symptoms during initiation 
of therapy with converting enzyme inhibitors; under steady 
state conditions, 90% of these events occur in patients with 
severe hyponatremia (14). Symptomatic hypotension may 
also occur in patients with a normal serum sodium concen-
tration, however, if they have recently experienced a pro-
found diuresis. Another 15 to 25% of patients with heart 
failure have hypotensive symptoms during maintenance 
treatment with captopril or enalapril, if volume depletion 
ensues during the course of therapy. These observations 
indicate that the renin-angiotensin system in some patients 
with heart failure is not simply a useless epiphenomenon 
reflecting circulatory failure, but plays a critical role in 
preserving systemic blood pressure. In these patients inter-
ference with angiotensin II biosynthesis removes the prin-
cipal vasoconstrictive support for maintaining systemic blood 
pressure and leads to cerebral hypoperfusion. 
Interference with the renin-angiotensin system may also 
disrupt those local homeostatic mechanisms that are critical 
to the preservation of renal function in patients with conges-
tive heart failure. As heart failure develops and renal blood 
flow decreases, the glomerular filtration rate is preserved 
by selective vasoconstriction of the efferent (postglomeru-
lar) arterioles. This mechanism permits patients with severe 
heart failure to maintain normal values for blood urea ni-
trogen and serum creatinine concentration despite a sub-
stantial decrease in cardiac output. There is compelling evi-
dence to indicate that effective operation of this compensatory 
mechanism is highly dependent on angiotensin II (12). Con-
sequently, even if only small decreases in systemic blood 
pressure occur during converting enzyme inhibition, glo-
merular filtration rate may decrease dramatically, because 
compensatory efferent arteriolar vasoconstriction cannot take 
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place in the absence of angiotensin II. Treatment with cap-
topril and enalapril, therefore, may produce marked azo-
temia in patients with congestive heart failure. This dete-
rioration of renal function may be reversed by reducing the 
patient's dependence on the renin-angiotensin system (for 
example, by reducing the dose of concomitantly adminis-
tered diuretic drugs). 
By stimulating the synthesis of aldosterone, the renin-
angiotensin system provides an important means by which 
the body maintains potassium homeostasis. If aldosterone 
secretion is suppressed by converting enzyme inhibition, 
the ability of the kidneys to excrete potassium becomes 
markedly impaired. The resulting increase in serum potas-
sium concentration might be expected to be self-limited, 
because of the known ability of potassium itself to stimulate 
aldosterone secretion, but this effect requires the presence 
of angiotensin II and does not occur during converting en-
zyme inhibition (16). In most patients with heart failure 
whose potassium stores are depleted by diuretic therapy, 
this increase in serum potassium concentration is not a ther-
apeutic problem. If potassium supplements are adminis-
tered, however, dangerous increases in serum potassium 
concentration may result, especially if renal function con-
comitantly deteriorates (17); similar hyperkalemic events 
may occur when converting enzyme inhibitors and spiron-
olactone are combined. 
The art of compromise: a clinical challenge. 
Therefore, despite its detrimental effects on cardiac func-
tion, the renin-angiotensin system plays a pivotal role in 
some patients with severe heart failure. Although many 
patients will benefit from long-term converting enzyme in-
hibition, others may be quite susceptible to interference with 
an important mechanism that has evolved to preserve cere-
bral and renal function and electrolyte balance. Identifica-
tion of patients with heart failure who are at greatest risk 
of developing adverse effects from captopril and enalapril 
is a worthwhile goal, but clinical experience has not pro-
vided the means to do so. Although hyponatremia identifies 
those patients most likely to experience symptomatic hy-
potension during the initiation of therapy (14), there are no 
means of predicting who will develop symptomatic hypo-
tension, worsening azotemia or hyperkalemia during long-
term converting enzyme inhibition, probably because changes 
in diuretic therapy and in dietary sodium intake continually 
modify each patient's dependence on angiotensin II in main-
taining circulatory homeostasis. Consequently, patients treated 
with captopril and enalapril need to be advised about the 
risk of symptomatic hypotension and require periodic bio-
chemical evaluation to detect drug-related azotemia and hy-
perkalemia; if such adverse events are observed, patients 
should be instructed to reduce the dose of diuretic drugs or 
avoid sources of supplemental potassium (salt substitutes). 
In this regard, converting enzyme inhibitors that are short-
acting may have an important advantage over longer-acting 
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agents, because long-tenn hemodynamic and clinical im-
provement does not appear to require continuous angiotensin 
II suppression (18), but the frequency and severity of ad-
verse effects (hypotension, azotemia and hyperkalemia) may 
be reduced by pennitting brief restoration of the homeostatic 
actions of the renin-angiotensin system (3). 
There is a price for interfering with evolution. Trying to 
interrupt the detrimental hemodynamic actions of the renin-
angiotensin system while simultaneously striving to preserve 
its beneficial circulatory functions may become an exacting 
challenge for the clinician treating the individual patient with 
congestive heart failure, a challenge that requires the con-
tinuous reevaluation of dietary sodium intake, dose of di-
uretic drug and dose and type of converting enzyme inhib-
itor. For some patients, amelioration of dyspnea can only 
be achieved at the cost of worrisome hypotension and con-
siderable (albeit usually asymptomatic) deterioration of renal 
function. 
You pays your money and you takes your choice. 
Aldous Huxley 
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